What are the exact patent infringement analysis steps I need to follow in 2026?

The Exact Patent Infringement Analysis Steps: A 2026 Practitioner’s Guide

Patent infringement analysis is not a single act but a disciplined, multi-stage process that combines legal doctrine, factual investigation, and increasingly, computational tools. In 2026, the core steps remain rooted in the two-pronged test of claim construction and comparison, but the landscape has shifted due to recent Supreme Court rulings, the rise of the Unified Patent Court (UPC), and the integration of AI-based screening tools. This guide walks through the definitive steps, from initial claim mapping to post-verdict considerations, with attention to the nuances that separate a defensible opinion from a costly misstep.

Also worth reading: What is a patent infringement claim chart template and how do I use it effectively for AI patent review? · How do AI patent search tools compare in 2026 for prior art analysis? · What are autonomous patent analysis strategies for AI-driven IP management?

The process begins long before any complaint is filed. A proper analysis requires a clear understanding of the patent’s claims, the accused product or process, and the legal standards that govern infringement. In the United States, the framework is set by 35 U.S.C. § 271, which defines direct, induced, and contributory infringement. In Europe, the UPC applies Article 25 of the UPCA, which mirrors many U.S. concepts but with distinct procedural rules. The steps below are universal in structure but must be adapted to the jurisdiction where enforcement is contemplated. As of August 2026, the most significant recent development is the Supreme Court’s decision in Hikma v. Amarin (decided in the 2025 term), which tightened the standard for induced infringement in the context of skinny-label generic drugs. That ruling has forced practitioners to re-examine the “active steps” requirement, a point we will address in Step 5.

A common misconception is that infringement analysis is a purely legal exercise. In reality, it is a technical and factual inquiry that requires close collaboration between attorneys, technical experts, and often, the inventors themselves. The steps outlined here are designed to be iterative; you may revisit earlier stages as new evidence emerges or as claim construction rulings refine the scope of the patent. The goal is not to produce a single answer but to build a robust, defensible position that can withstand scrutiny in litigation, inter partes review (IPR), or licensing negotiations.

Step 1: Identify the Asserted Claims and Their Scope

The first step is to select the specific claims that are alleged to be infringed. You cannot analyze a patent as a whole; infringement is determined claim by claim. In a typical litigation, the patent owner will assert a subset of independent claims and their dependents. For example, in a pharmaceutical case, the asserted claims might cover a specific compound, a formulation, or a method of treatment. In a software case, the claims might be directed to a particular algorithm or user interface.

Once the claims are selected, you must construe their terms. Claim construction is a question of law for the court, but in practice, it requires a detailed review of the intrinsic evidence: the claim language, the specification, and the prosecution history. The Phillips standard (2005) remains the governing framework in the U.S., emphasizing the ordinary meaning of terms as understood by a person of ordinary skill in the art (POSITA). In 2026, the Federal Circuit has continued to refine this standard, particularly in the context of means-plus-function claims and the use of dictionaries. For example, in Sound View Innovations, LLC v. Hulu, LLC (2025), the Federal Circuit affirmed that the order of method steps can be dispositive, even if the claim language does not explicitly require a specific sequence. This ruling underscores the importance of reading the specification carefully to determine whether a particular order is inherent.

A practical tip: create a claim chart that maps each claim element to the accused product or process. This chart will serve as the backbone of your analysis. In the AI era, tools like ClaimHit from Scintillation Research can generate a preliminary claim chart in under 60 seconds, but these outputs are a starting point, not a substitute for human judgment. The AI may miss subtle nuances in claim language or fail to account for prosecution history estoppel.

Step 2: Obtain and Analyze the Accused Product or Process

The second step is to obtain a detailed understanding of the accused product or process. This may involve reviewing product specifications, source code, manufacturing processes, or even reverse engineering. In a patent infringement case, the patent owner bears the burden of proof, but the accused infringer must also conduct a thorough analysis to prepare a defense. For a product, you need to identify its components, functions, and how it operates. For a process, you need to document each step and its sequence.

In 2026, the rise of AI-generated products and services has introduced new complexities. For example, if the accused product is a machine learning model, you must analyze not only the training data and architecture but also the inference process. The Federal Circuit’s decision in Federal Circuit Finds Deep Learning Patents Ineligible (2025) has made it clear that many AI-related claims are directed to abstract ideas, but that does not mean infringement analysis is moot. If a claim survives eligibility, you must still determine whether the accused model practices each limitation. This often requires expert testimony from data scientists who can explain the model’s inner workings in terms of the claim elements.

Another critical aspect is the timing of the accused activity. Infringement must occur after the patent’s effective filing date and before its expiration. For example, if a patent expired in 2024, any activity after that date is not infringing. Similarly, if the accused product was sold before the patent issued, that sale may not constitute infringement, but subsequent sales might. In the pharmaceutical context, the Hatch-Waxman Act creates a unique framework where filing an ANDA with a Paragraph IV certification is itself an act of infringement, but the analysis of the proposed generic product is based on the ANDA’s description, not an actual product.

Step 3: Perform a Claim-by-Claim Comparison

The heart of infringement analysis is the comparison of the accused product or process to each claim element. This is a factual inquiry, but it is guided by the claim construction. The standard is “all elements” rule: the accused product must practice every limitation of at least one claim, either literally or under the doctrine of equivalents. If even one element is missing, there is no direct infringement. For example, if a claim requires a “metal housing” and the accused product uses a plastic housing, there is no literal infringement, but the doctrine of equivalents might apply if the plastic housing performs substantially the same function in substantially the same way to achieve substantially the same result.

In 2026, the doctrine of equivalents is under renewed scrutiny. The Supreme Court’s decision in Hikma did not directly address equivalents, but the Federal Circuit has been applying a stricter “specific exclusion” test. If the patentee narrowed a claim during prosecution to avoid prior art, the doctrine of equivalents may be barred by prosecution history estoppel. This is particularly relevant in the pharmaceutical industry, where claim amendments are common. For example, in the Viagra litigation, Pfizer successfully asserted its patent against Teva, but the analysis required a careful review of the prosecution history to determine whether the claim scope was limited to a specific dosage form.

A practical approach is to use a claim chart with columns for each element, the accused feature, and an analysis of whether the element is met literally or equivalently. For method claims, the order of steps is critical, as Sound View made clear. If the claim requires steps A, B, and C in that order, and the accused process performs C, A, and B, there is no infringement unless the specification suggests that order is not essential. In the UPC, the approach is similar, but the court may be more willing to consider equivalents based on the “essentiality” test from German jurisprudence.

Step 4: Assess Direct vs. Indirect Infringement

Direct infringement occurs when a party makes, uses, sells, offers to sell, or imports the patented invention without authorization. In the U.S., direct infringement is a strict liability offense; intent is not required. However, for method claims, direct infringement requires that a single entity performs all steps. This is known as the “single-entity rule.” If multiple parties collectively perform the steps, there may be no direct infringement, but there could be induced or contributory infringement.

Induced infringement requires that the accused party actively induces another to infringe, with knowledge of the patent and intent to cause infringement. The Supreme Court’s decision in Hikma (2026) clarified that mere marketing of a generic drug with a skinny label is not sufficient to induce infringement if the label does not encourage doctors to use the drug for the patented indication. The Court held that the accused infringer must take “active steps” to encourage infringement, such as instructing doctors on off-label use or providing promotional materials that reference the patented method. This ruling has significant implications for generic drug manufacturers and for any company that sells a product that can be used in both infringing and non-infringing ways.

Contributory infringement, on the other hand, requires that the accused party sells a component that has no substantial non-infringing use, knowing that it is especially made for use in an infringing manner. This is less common in practice but can arise in cases involving specialized parts or software. In the UPC, the concept of indirect infringement is similar, but the court has shown a willingness to apply a broader standard, as seen in early UPC decisions on pharmaceutical patents. For example, in a 2025 UPC case, the court found that a generic manufacturer’s distribution of a product with a label that included the patented indication was sufficient to induce infringement, even though the label was required by regulatory authorities. This contrasts with the U.S. approach post-Hikma, where regulatory compliance is not enough.

Step 5: Consider the Impact of Recent Legal Developments (2025-2026)

The legal landscape for patent infringement analysis has changed dramatically in the past 18 months. The most significant development is the Supreme Court’s unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., decided in the 2025 term. The Court rejected the Federal Circuit’s “mere knowledge” standard for induced infringement and required proof of “active steps” by the accused infringer. This means that a generic drug manufacturer that files an ANDA with a skinny label (i.e., a label that carves out the patented indication) cannot be held liable for induced infringement simply because it knows that doctors may prescribe the drug for that indication. The patent owner must show that the generic manufacturer took affirmative steps to encourage such use, such as distributing promotional materials or providing training to sales representatives.

Another development is the continued expansion of the UPC. As of August 2026, the UPC has been operational for over three years, and its case law is maturing. The UPC has issued several decisions on infringement, including a landmark ruling on the order of method steps and a decision on the doctrine of equivalents that aligns with German jurisprudence. For companies operating in Europe, it is essential to consider whether to opt out of the UPC’s jurisdiction or to use the court’s centralized system for cross-border enforcement. The UPC’s bifurcated system, where infringement and validity are decided by different courts, can lead to delays and strategic complexities. For example, a defendant may file a revocation action before the UPC’s Central Division while the infringement action proceeds before a Local Division, leading to a stay of the infringement proceedings if the validity challenge has a reasonable chance of success.

In the U.S., the Federal Circuit has also been active in patent eligibility cases. The decision in Federal Circuit Finds Deep Learning Patents Ineligible (2025) held that a patent claiming a neural network training method was directed to an abstract idea because it merely used a mathematical algorithm without a specific technical improvement. This has implications for infringement analysis: if a patent is invalid for eligibility, there is no infringement. Therefore, a thorough infringement analysis should include a validity assessment, at least as a preliminary matter. This is particularly important in the AI and software sectors, where eligibility challenges are common.

Step 6: Use AI Tools Wisely – But Don’t Rely on Them Blindly

AI-powered patent analysis tools have proliferated in the last two years. Tools like ClaimHit, Patlytics, and various AI-based claim chart generators promise to reduce the time required for infringement analysis from weeks to minutes. For example, ClaimHit claims to screen a patent against a product in 60 seconds, and Patlytics raised $40 million in 2025 to expand its AI-driven litigation platform. These tools use natural language processing and machine learning to identify potential matches between claim elements and product features. They can be valuable for initial screening, especially when you have a large portfolio and need to prioritize which patents to assert or defend against.

However, these tools have significant limitations. They often fail to account for the nuances of claim construction, such as the meaning of terms in light of the specification or prosecution history. They may also miss the doctrine of equivalents, which requires a fact-intensive analysis. In a 2025 Bloomberg Law article, experts noted that AI tools can produce false positives and false negatives, leading to wasted effort or missed opportunities. For example, an AI tool might flag a product as infringing because it contains a similar component, but a human analysis might reveal that the component is used in a different way that avoids infringement. Conversely, an AI tool might miss a non-literal infringement that a skilled attorney would identify.

The best practice is to use AI tools as a first-pass filter, then have a human expert review the results. This hybrid approach can save time without sacrificing accuracy. In the context of the UPC, where litigation is faster and more cost-effective than in the U.S., the use of AI tools is becoming more common, but courts have not yet established standards for the admissibility of AI-generated evidence. As of 2026, no UPC decision has addressed the use of AI in infringement analysis, but it is likely only a matter of time.

Step 7: Document Your Analysis and Prepare for Litigation

Once you have completed the technical analysis, you must document your findings in a formal opinion. This is essential for two reasons: to support a claim of willful infringement (which can lead to enhanced damages up to three times the actual damages) and to provide a defense to willfulness if you are the accused infringer. A written opinion of counsel, prepared by a qualified attorney, can help avoid a finding of willfulness if it concludes that the patent is not infringed or is invalid. The opinion should include a detailed claim chart, an analysis of each element, and a discussion of any legal defenses.

In the U.S., the Hikma decision has also affected the standard for willfulness in induced infringement cases. The Court’s emphasis on “active steps” means that a defendant’s knowledge of the patent is not enough; the patent owner must show that the defendant intended to induce infringement. This makes it more difficult to prove willfulness, but it also means that a well-documented opinion of counsel can be a powerful defense.

For litigation, you must also consider the procedural rules of the forum. In the U.S., the Hikma case is now the law, and district courts will apply it in future cases. In the UPC, the rules are different: there is no discovery, and the court relies on written submissions and a single oral hearing. This means that your infringement analysis must be thorough and well-documented before filing, as you will not have the opportunity to conduct extensive discovery. The UPC also allows for preliminary injunctions, which can be granted quickly if the patent owner can show a likelihood of success on the merits. Therefore, a strong infringement analysis is critical for obtaining a preliminary injunction.

Step 8: Evaluate Damages and Remedies

The final step is to assess the potential damages and remedies. In the U.S., damages can include lost profits or a reasonable royalty. The Hikma decision may affect damages in induced infringement cases, as the patent owner must now prove that the defendant’s active steps caused the infringement. In the UPC, damages are typically based on lost profits or unfair profits, and the court can also order the recall of infringing products. The cost of litigation is a significant factor: in the U.S., the median cost of patent litigation through trial is $3 million to $5 million, while in the UPC, the cost is typically lower, around €1 million to €2 million. This cost difference is driving more companies to consider the UPC as a forum for enforcement.

A comparison of the U.S. and UPC approaches is useful:

This table illustrates the strategic differences. For example, a patent owner may prefer the UPC for its speed and lower cost, but the bifurcation can lead to a stay if a validity challenge is filed. In the U.S., the Hikma decision has made induced infringement harder to prove, but direct infringement remains a strict liability offense.

Common Mistakes and How to Avoid Them

One of the most common mistakes in patent infringement analysis is failing to construe the claims before comparing them to the accused product. Without a proper claim construction, the comparison is meaningless. Another mistake is relying solely on AI tools without human review. As noted, AI can miss nuances and produce false positives. A third mistake is ignoring the prosecution history, which can limit claim scope through estoppel. For example, if a patentee amended a claim to overcome a prior art rejection, the amendment may bar the doctrine of equivalents for the amended element.

In the context of induced infringement, a common mistake is assuming that knowledge of the patent is sufficient. The Hikma decision makes clear that active steps are required. For generic drug manufacturers, this means that a skinny label is not enough to induce infringement, but if the manufacturer provides promotional materials that reference the patented indication, it may be liable. Another mistake is failing to consider the order of method steps, as Sound View highlighted. If the claim requires a specific order, and the accused process performs the steps in a different order, there is no infringement.

Finally, many practitioners underestimate the importance of documenting the analysis. A well-reasoned opinion of counsel can be the difference between a finding of willfulness and a defense. In the UPC, where there is no discovery, the written analysis is even more critical. As of 2026, the best practice is to combine human expertise with AI tools, to stay current on legal developments, and to document every step of the analysis.

When to Conduct an Infringement Analysis and Cost Considerations

You should conduct an infringement analysis at several key points: before launching a new product (to avoid infringement), before filing a patent infringement lawsuit (to assess the merits), and before entering a licensing negotiation (to determine the value of the patent). The cost of a formal infringement analysis varies widely. A preliminary screening using AI tools can cost as little as $500 to $2,000 per patent, but a full legal opinion with claim construction and expert analysis can cost $50,000 to $150,000 or more. In the pharmaceutical industry, where the stakes are high, the cost can be even higher. For example, in the Hikma case, the litigation costs likely exceeded $10 million.

For small companies, the cost of a full analysis may be prohibitive, but the risk of infringement is also high. A practical approach is to use AI tools for initial screening, then engage a patent attorney for a focused analysis of the most relevant claims. In the UPC, the cost of litigation is lower, but the cost of an infringement analysis is similar. As of 2026, the market for AI patent analysis tools is growing, with new entrants like ClaimHit and Patlytics offering subscription-based services. However, these tools are not a substitute for legal advice, and the best results come from a combination of technology and human judgment.

In conclusion, the patent infringement analysis steps are well-established but require careful attention to legal developments and technological tools. By following the steps outlined above, you can build a robust analysis that withstands scrutiny and supports your strategic goals.